(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Banks for High Fixed Store Rates: Augment Your Investment funds - 2All that You Really want to Be aware of Dental Inserts Facilities
- 3Jesse Jackson hospitalized, under observation for a neurodegenerative condition
- 4Finding China: Four Urban areas for a Remarkable Excursion
- 5Instructions to Utilize the Towing Highlights of the Slam 1500 Productively.
- The most effective method to Refresh the Infotainment Framework in the Volvo XC40
- The Manual for Well known rough terrain Vehicles
- 'Heated Rivalry' is just the tip of the iceberg. How hockey became the sexiest sport
- First Greenland, now Iceland? Annexation joke by Trump ally gets frosty response in the Arctic nation.
- Mussolini's summer villa on Adriatic coast sold for €1.2 million
- Iranian strikes on Israel injure 11 and set chemical plant ablaze
- Saturn's moon Titan may not have a buried ocean as long suspected, new study suggests
- NASA's giant moon rocket, in photos
- CVS forecasts 2026 profit above estimates on strong performance
